Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)

Launched by LANCASTER GENERAL HOSPITAL · Nov 12, 2024

Keywords

ClinConnect Summary

The DCM-DETECT clinical trial is studying how to better detect dilated cardiomyopathy (DCM), a type of heart disease, using mobile technology and artificial intelligence (AI). In this study, patients diagnosed with DCM will invite their close family members, known as first-degree relatives (like children or siblings), to participate in a heart screening using a mobile device. The goal is to identify any potential heart issues early, especially among those who may be at higher risk due to their family connection.

To participate, you need to be at least 18 years old, have a confirmed diagnosis of non-ischemic dilated cardiomyopathy, and have at least one living adult family member who can also join the screening. Participants will use a smartphone or tablet to complete the screening, which is designed to be convenient and accessible. If you're interested, this trial provides an opportunity to learn more about your heart health and the health of your family members, potentially leading to earlier diagnosis and better management of heart conditions.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria (Proband)
• • Male or female age ≥ 18 years
• • Confirmed diagnosis of non-ischemic DCM determined at the discretion of the treating physician and defined as LVEF ≤ 45% at any time during the clinical course of the patient
• • Must have at least one living adult FDR
• • Able to provide informed consent
• • Inclusion Criteria (FDR)
• • Male or female age ≥ 18 years who are first-degree relatives of patients with DCM
• • Proband has provided informed consent
• • FDR able to provide informed verbal consent
• • Access to a smartphone or digital tablet with cellular data or Wi-Fi access
• • Exclusion Criteria (Proband)
• • DCM attributed to any other secondary form of cardiomyopathy per the investigator's determination
• • Proband has previously informed FDR to undergo cardiac screening
• • Ischemic cause of reduced LVEF
• • evidence of myocardial infarction, inducible ischemia or chest pain on stress testing in absence of coronary angiogram to rule out ischemic disease
• • history of acute coronary syndromes (STEMI (ST-Elevation Myocardial Infarction), NSTEMI (Non-ST-Elevation Myocardial Infarction) or unstable angina) revascularization or ≥75% stenosis of either left main or Left Anterior Descending (LAD) or ≥75% stenosis of 2 major epicardial vessels on angiogram
• • Moderate or greater primary valvular abnormality not due to underlying cardiomyopathy
• • Congenital structural heart disease
• • Severe and untreated or untreatable hypertension
• • Cardiomyopathy due to acute or reversible conditions; examples include tachyarrhythmias, thyroid disorders, iron overload
• • Any secondary cause of reduced LVEF such as pregnancy, myocarditis, amyloidosis, sarcoidosis, exposure to toxins including alcohol, substance abuse or chemotherapeutic drug
• • (CPC Participants only) Home address outside of traveling range
• • Exclusion Criteria (FDR)
• • Previously informed about cardiac screening or has completed cardiac screening by transthoracic echocardiogram (TTE)
• • Previously diagnosed with reduced LVEF
• • (CPC Participants only) Home address outside of traveling range